Life after DIAS II

Abstract

Get full access to this article

View all access options for this article.

References

The Internet Stroke Centre. DIAS-2 desmoteplase in acute ischemic stroke. http://www.Strokecenter.Org/trials/trialdetail.Aspx?Tid=515, 2007.

The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7.

The Internet Stroke Centre. The International Stroke Trial (IST 3). http://www.Dcn.Ed.Ac.Uk/ist3/, 2007.

The Internet Stroke Centre. Epithet: Echoplanar imaging thrombolysis evaluation trial: http://www.Strokecenter.Org/trials/trialdetail.Aspx?-Tid=420, 2007.

Hacke

Albers

Al-Rawi

. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9–hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66–73.

Albers

Thijs

Wechsler

. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (defuse) study. Ann Neurol 2006; 60: 508–17.

Barber

Davis

Darby

. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra. Neurology 1999; 52: 1125–32.

Parsons

Barber

Chalk

. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51: 28–37.

Furlan

Eyding

Albers

. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227–31.